Pharmaceutical Sciences

Pharmaceutical Sciences Experts

Mark Mcgovern

Board of Director
United States of America


 Mark E. McGovern was appointed to our board of directors in February 2014. Mark is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies. His experience includes 11 years at Bristol-Myers Squibb, where Mark was responsible for the clinical development of pravastatin (Pravachol®), in particular the programs for atherosclerosis regression and coronary heart disease prevention, including the WOSCOPS (West of Scotland Coronary Prevention Study), CARE (Cholesterol and Recurrent Events), and LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trials. He subsequently spent 10 years at Kos Pharmaceuticals, where he last served as Executive Vice President, Medical Affairs, and Chief Medical Officer. During his career at Kos, Mark oversaw the phase IV trials of extended-release niacin (Niaspan®), and the registration programs for the first combination lipid therapies, niacin extended-release/lovastatin (Advicor®) and niacin extended release/simvastatin (Simcor®). He currently serves as a consultant to the pharmaceutical industry for cardiovascular and atherosclerosis drug development. Mark earned his bachelor’s degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Mark is a Fellow of the American College of Cardiology and the American College of Physicians. He has published extensively on lipid management and its role in the treatment of coronary heart disease.

Research Interest

 Cardiovascular and atherosclerosis drug development,cardiology

Global Experts from United States of America

Global Experts in Subject

Share This Profile